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a b s t r a c t
Ubiquitin C-terminal Hydrolase L1 (UCH-L1) has oncogenic properties and is highly expressed during
malignancies. We recently documented that Epstein-Barr virus (EBV) infection induces uch-l1 expression.
Here we show that Kaposi's Sarcoma-associated herpesvirus (KSHV) infection induced UCH-L1 expres-
sion, via cooperation of KSHV Latency-Associated Nuclear Antigen (LANA) and RBP-Jκ and activation of
the uch-l1 promoter. UCH-L1 expression was also increased in Primary Effusion Lymphoma (PEL) cells co-
infected with KSHV and EBV compared with PEL cells infected only with KSHV, suggesting EBV augments
the effect of LANA on uch-l1. EBV latent membrane protein 1 (LMP1) is one of the few EBV products
expressed in PEL cells. Results showed that LMP1 was sufﬁcient to induce uch-l1 expression, and co-
expression of LMP1 and LANA had an additive effect on uch-l1 expression. These results indicate that
viral latency products of both human γ-herpesviruses contribute to uch-l1 expression, which may
contribute to the progression of lymphoid malignancies.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) is a cysteine
hydrolase that contains the typical active site triad of cysteine,
histidine, and aspartic acid and catalyzes hydrolysis of C-terminal
esters and amides of ubiquitin (Larsen et al., 1996). In adult
humans, UCH-L1 is normally exclusively expressed in the brain
and cells of the reproductive system (Kwon et al., 2004; Setsuie
and Wada, 2007). Although the physiological function of UCH-L1
in neurons is still unclear, mutations in the uch-l1 gene have been
associated with Parkinson's and Alzheimer's diseases (Betarbet
et al., 2005). Functional activities, other than acting as an ubiquitin
hydrolase, have been proposed for UCH-L1. First, UCH-L1 can
dimerize resulting in ubiquitin ligase activity (Liu et al., 2002).
Second, in neurons, the stabilization of mono-ubiquitinated pro-
teins is not dependent on UCH-L1 deubiquitinating activity (Osaka
et al., 2003; Setsuie and Wada, 2007), a ﬁnding that points to an
ubiquitin-independent function for UCH-L1.
Besides the high levels of expression of UCH-L1 in the brain and
reproductive system, de novo expression of UCH-L1 has been
detected in numerous cancers, such as lung (Hibi et al., 1999;
Kim et al., 2009), colorectal (Loefﬂer-Ragg et al., 2005), bladder
(Yang et al., 2006) and breast cancer (Miyoshi et al., 2006), and
points to the involvement of this protein in the oncogenic
transformation of cells. High levels of UCH-L1 were also observed
in transformed cells of lymphoid origin such as Burkitt lymphoma
(Ovaa et al., 2004) and multiple myeloma (Otsuki et al., 2004).
Recent studies demonstrate that inhibition of the expression of
UCH-L1 reduces the tumorigenic phenotype of transformed cells,
including EBV-transformed B-lymphocytes (Bheda et al., 2009a;
Kim et al., 2009; Rolen et al., 2008). UCH-L1 also associates with
cytoskeletal components, including microtubules (Bheda et al.,
2010; Kabuta et al., 2008) and actin ﬁlaments (Basseres et al.,
2010), and it physically associates with mitotic spindles (Bheda
et al., 2010), which suggests a potential role in the regulation of
mitosis. Furthermore, oncogenic transcription factors, such as
B-Myb and β-catenin/TCF, up-regulate the expression of the uch-
l1 gene (Bheda et al., 2009b; Long et al., 2003). Together, these
ﬁndings strongly support the idea of an oncogenic function for
UCH-L1, and although the physiological roles of UCH-L1 and the
regulation of its expression in normal and transformed cells
remain largely unexplored, it has become clear that this multi-
functional protein of the ubiquitin system UCH-L1 participates in
diverse cellular processes.
Both EBV and KSHV are members of the γ-herpesvirus sub-
family. EBV, the ﬁrst human tumor virus discovered, causes or is
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closely associated with both lymphoid and epithelial malignancies,
and KSHV is the causative agent of Kaposi's sarcoma, Multicentric
Castleman's disease, and primary effusion lymphoma (PEL)
(Pagano, 2009; Sin et al., 2007). Both viruses produce signiﬁcant
pathology in immunodeﬁcient hosts, most commonly in patients
with AIDS (Pagano, 2009; Sin et al., 2007).
During cell transformation by EBV, viral oncoproteins disrupt a
variety of host signaling pathways that affect the host ubiquitin
system (Pagano, 2009; Shackelford and Pagano, 2005, 2007). The
EBV primary oncogene LMP1 inhibits Siah1 ubiquitin ligase and
stabilizes the expression of β-catenin (Jang et al., 2005). LMP1 also
induces the regulatory ubiquitination of IRF7 (Ning et al., 2008) as
well as downregulates the activity of IRF7 via the activation of the
ubiquitin-editing enzyme A20 (Ning and Pagano, 2010). EBNA1
competes with p53 to interact with HAUSP, the p53 deubiquitinat-
ing enzyme, thus indirectly targeting p53 for ubiquitination and
degradation (Holowaty and Frappier, 2004; Holowaty et al., 2003).
EBNA3C, which possesses intrinsic deubiquitinating activity, inhi-
bits the p53 and Rb pathways by two different mechanisms:
deubiquitination of MDM2 and recruitment of SCF4 ligase (Saha
et al., 2009; Ying and Xiao, 2006).
The main KSHV protein that directly or indirectly affects the
host ubiquitin system is Latency-Associated Nuclear Antigen
(LANA), which is expressed in all KSHV latently infected cells
and modulates cellular pathways that may contribute to tumor-
igenesis (Wen et al., 2004). LANA physically associates with p53
and inhibits p53-mediated transcriptional activity and apoptosis
(Freiborg et al., 1999). LANA also inactivates expression of the
tumor suppressor retinoblastoma (Rb) and releases the transacti-
vator E2F, which induces cells to progress through the G1/S cell
cycle checkpoint. In addition, LANA interacts with the
bromodomain-containing protein RING3/Brd2 and further stimu-
lates cell-cycle progression. Together, p53 regulation and cell-cycle
progression are highly regulated by the host ubiquitin system.
Finally, LANA rescues β-catenin from phosphorylation-dependent
ubiquitination and destruction by interacting with GSK3 β
(Fujimuro et al., 2007).
LANA functions as a transcriptional modulator of multiple
cellular and viral promoters, including its own (Jeong et al.
2004; Garber et al. 2001). It can both activate as well as repress
transcription of multiple viral and cellular genes through a variety
of mechanisms. Furthermore, LANA can act as a transcriptional
modulator both directly and indirectly. LANA binds DNA, including
the KSHV terminal repeat and its own promoter, and regulates
gene expression. LANA also interacts with p53 and down-regulates
its transcriptional activity; however, it can also bind pRb and
activate E2F-dependent gene transcription. Additionally, LANA
regulates transcription by binding to and inhibiting the histone
transferase activity of CREB-binding protein (CBP). Finally, LANA
associates with cellular chromatin and remains associated with
chromosomes during cell division.
Recently, we have shown that immortalization of peripheral
blood mononuclear cells (PBMCs) with EBV activates uch-l1
(Ballestas and Kaye 2011). In type III EBV latency, EBV Nuclear
Antigen 2 (EBNA2) forms complexes with the transcription factor
PU.1, activating the uch-l1 promoter and inducing UCH-L1 RNA and
protein expression (Bheda et al., 2011). In addition, HPV16-
mediated transformation induces uch-l1 expression in normal
keratinocytes (Rolen et al., 2009). We therefore hypothesize that
in the process of cellular transformation, tumor viruses activate
the uch-l1 promoter, thus inducing UCH-L1 protein expression and
dysregulation of the host ubiquitin system. We now show, for the
ﬁrst time, that infection of human endothelial cells with KSHV
results in increased endogenous UCH-L1 expression in these cells
and that KSHV LANA along with RBP-Jκ activates the uch-l1
promoter. In addition, we demonstrate that EBV LMP1 can also
activate the uch-l1 promoter and increase levels of UCH-L1. Finally,
we ﬁnd that in a primary effusion lymphoma (PEL) cell line dually
infected with EBV and KSHV endogenous UCH-L1 RNA and protein
levels are increased to a greater extent than in PELs infected with
KSHV only. These observations demonstrate a mechanism by
which KSHV and EBV infections lead to cell transformation and
suggest that infection with multiple tumor viruses may have an
additive effect on UCH-L1 expression.
Results
KSHV infection of endothelial cells induces the expression of UCH-L1
Human Umbilical Vein Endothelial Cells (HUVECs) were
infected with a recombinant KSHV expressing green ﬂuorescent
protein (GFP), and a stable KSHV-HUVEC cell line was generated as
described before (Wang et al., 2006). Equivalent microgram
amounts of lysates from HUVECs and KSHV-HUVECs were sub-
jected to 2D protein gel electrophoresis analysis, and gels were
stained with Coomassie Blue dye. Spots that were differentially
expressed in the HUVEC and the KSHV-HUVEC cells were excised
from the gel and identiﬁed by mass spectrometry (Fig. 1A). One
protein upregulated in KSHV-HUVECs, but not HUVECs, was the
cysteine hydrolase UCH-L1 (Fig. 1A), suggesting that KSHV infec-
tion induces the expression of UCH-L1.
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Fig. 1. UCH-L1 expression is induced in endothelial cells after infection with KSHV. (A) Equivalent microgram amounts of HUVEC and KSHV-HUVEC cell lysates were
subjected to 2D gel electrophoresis analysis following which the gels were stained with Coomassie blue. Two of the differentially expressed spots, identiﬁed by mass
spectrometry, were UCH-L1 and GFP (arrows). (B) RNA from HUVEC and KSHV-HUVEC was isolated and subjected to RT-PCR using uch-l1 and β-actin primers. (C) Equivalent
amounts of KSHV-HUVEC and HUVEC cell lysates were subjected to SDS-PAGE and immunoblotted with UCH-L1 or actin antibodies. Relative expression was determined by
densitometry. All results are shown as the mean7standard deviation for experiments performed in triplicate.
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To determine whether UCH-L1 was upregulated at the tran-
scriptional level, RNA was isolated from these cells, and RT-PCR
was performed. KSHV-HUVECs had increased levels of UCH-L1
RNA compared with the uninfected cells (Fig. 1B). Similar results
were observed when examining UCH-L1 protein levels (Fig. 1C);
where UCH-L1 levels in infected cells were greater than in
uninfected cells. Relative UCH-L1 expression was determined for
experiments performed in triplicate (Fig. 1B and C), and results
showed a signiﬁcant (po0.05) increase in UCH-L1 gene and
protein expression in KSHV-infected HUVECs. These results corro-
borate the 2D proteomic analysis and demonstrate that KSHV
infection induces the expression of UCH-L1.
KSHV LANA interacts with UCH-L1 and induces the endogenous
expression of UCH-L1
To begin to decipher the KSHV-speciﬁc protein(s) required for
the observed KSHV-induced upregulation of UCH-L1 expression,
we focused on LANA, which is expressed in the majority of KSHV-
infected cells. First, the ability of KSHV LANA to interact with UCH-
L1 was examined in Cos-7 cells, which express intermediate levels
of endogenous UCH-L1 (Bheda et al., 2009a). Immunoprecipita-
tions showed that an interaction between over-expressed LANA
and endogenous UCH-L1 could be detected (Fig. 2A). Additionally,
when total cell lysates were probed with UCH-L1-speciﬁc anti-
bodies, the results revealed signiﬁcantly (po0.05) higher levels of
UCH-L1 (two-fold increase) in LANA-expressing cells compared
with vector-containing cells (Fig. 2A). NIH 3T3 cells, which express
very low levels of UCH-L1 (Bheda et al., 2009a), were used to
conﬁrm these ﬁndings. Results showed that NIH 3T3 cells trans-
fected with Flag-LANA exhibited more than a three-fold increase
(po0.001) in the expression of endogenous UCH-L1 RNA and
protein levels (Fig. 2B and C) when compared with control-
expressing cells. In addition, LANA induced UCH-L1 expression in
a dose-dependent manner (Fig. 2D).
Because UCH-L1 expression appeared to be induced by LANA at
the transcriptional level, the ability of LANA to activate the uch-l1
promoter was tested with the use of a UCH-L1p-LUC reporter
construct, which contains a minimal endogenous uch-l1 promoter
region (Bheda et al., 2009a). Results showed that LANA expression
produced a signiﬁcant (po0.05) three-fold increase in activation
of the uch-l1 promoter when compared with control cells (Fig. 2D
and E). Together, these data indicate that KSHV LANA induces
UCH-L1 expression at the transcriptional level via its ability to
activate the uch-l1 promoter.
EBV increases levels of UCH-L1 in dually infected primary effusion
lymphoma cells
In addition to Kaposi's sarcoma, KSHV is detected in 100% of
primary effusion lymphomas (PELs) (Carbone et al., 2000; Carbone
and Gloghini, 2005; Fakhari et al., 2006; Sin et al., 2007). PELs, a
unique form of non-Hodgkin B-cell lymphomas found usually in
KSHV-infected patients with AIDS, are an aggressive, rapidly
progressing malignancy that is fatal (Carbone and Gloghini,
2005; Petre et al., 2007). Because LANA is one of the KSHV genes
that is expressed in PELs (Fakhari et al., 2006), the effect of KSHV
on uch-l1 expression in two representative PEL cell lines was
examined. We reported previously that naïve B cells contain
undetectable levels of UCH-L1 RNA and protein (Bheda et al.,
2009a; Bheda et al., 2011). However, analysis of two PEL cell lines
(BC-1 and BC-3) revealed detectable yet different levels of UCH-L1
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Fig. 2. KSHV LANA is associated with endogenous UCH-L1 and induces expression of UCH-L1. (A) Cos7 cells were transfected with control or LANA-Flag expression vectors
and harvested 48 h post-transfection for immunoprecipitation analysis. LANA-Flag was immunoprecipitated with anti-Flag-agarose beads. IPs and cell lysates were resolved
on 10–12% SDS-PAGE and probed with UCH-L1 and Flag antibodies. (B and C) Total RNA and protein were extracted from cells co-transfected with LANA or control expression
constructs. (B) RT-PCR analysis was performed using primers speciﬁc for uch-l1 and gapdh. (C) Western blot analyses for UCH-L1 protein levels in lysates from cells
transfected with or without LANA were performed with UCH-L1 antibodies. GAPDH was used as loading control. (D) Cells were transfected with different amounts of Flag-
LANA or vector-control expressing plasmids and Western blot analyses to detect UCH-L1 was performed. Relative expression was determined by densitometry, and results
are shown as the mean fold change7standard deviation for experiments performed in triplicate. (E) NIH3T3 cells were co-transfected with control or LANA-Flag expression
vectors (350 ng/well) along with UCH-L1p-LUC wild type reporter plasmid (500 ng/well) and β-gal expression constructs (250 ng/well). Luciferase assays were performed
48 h post-transfection. The data are shown as the mean7standard deviation for three independent experiments in triplicate and normalized to β-gal activity.
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RNA and protein (Fig. 3A and B). BC-1 cells expressed more than
four-fold higher (po0.05) levels of both UCH-L1 RNA and protein
compared with BC-3 cells. In addition, endogenous uch-l1 promo-
ter activity was signiﬁcantly (po0.05) greater in BC-1 cells than in
BC-3 cells. These ﬁndings demonstrate that KSHV-mediated cel-
lular transformation can induce uch-l1 expression.
One of the major differences between BC-1 and BC-3 cells is
that BC-3 cells are only infected with KSHV while BC-1 cells are
infected with both KSHV and EBV (Carbone et al., 2000; Carbone
and Gloghini, 2005; Fakhari et al., 2006; Sin et al., 2007). While the
role of EBV in PEL co-infection has been little explored and
remains obscure, there are reports that suggest that EBV and
KSHV can regulate each other's viral gene expression (Fan et al.,
2005b; Groves et al., 2001a; Krithivas et al., 2000; Xu et al., 2007).
EBV LMP1 induces the expression of UCH-L1
We have implicated EBNA2 in the EBV-mediated induction of
UCH-L1 expression (Bheda et al., 2009a,b, 2010, 2011); however,
PEL cells exhibit a restricted expression pattern of EBV proteins
and lack detectable expression of EBNA2 as well as EBNA3-6
(Callahan et al., 1999). Instead, dually infected PEL cells express
low levels of LMP1 (Carbone et al., 2000; Carbone and Gloghini,
2005; Fakhari et al., 2006; Sin et al., 2007), a constitutively active
transmembrane receptor that indirectly activates host-cell tran-
scription (Hatzivassiliou and Mosialos, 2002; Lam and Sugden,
2003; Li and Chang, 2003; Zheng et al., 2007). Analysis of the uch-
l1 promoter revealed putative binding sites for NF-κB, STATs, AP1,
c-Jun, SP1, SP3 and AP2-α all of which are the major downstream
targets of signaling pathways activated by LMP1.
To investigate whether LMP1 can affect endogenous uch-l1
expression, reporter assays were performed to examine the
activation of the endogenous uch-l1 promoter. Results showed
that LMP1 expression correlated with a signiﬁcant (po0.05) 2.5-
fold increase in the activation of the uch-l1 promoter when
compared with control-expressing cells (Fig. 4A). In addition, over
ﬁve-fold increases (po0.05) in levels of endogenous UCH-L1 RNA
and protein were detected in cells expressing LMP1 compared
with control cells (Fig. 4B and C). LMP1 also induced the expres-
sion of UCH-L1 in a dose-dependent manner (Fig. 4D). These data
indicate that EBV LMP1 can induce the UCH-L1 endogenous
expression in cells by activating its promoter.
KSHV LANA and EBV LMP1 together induce the expression of UCH-L1
Because the data showed enhanced activation of the uch-l1
promoter as well as increased UCH-L1 RNA and protein expression
in cells co-infected with KSHV and EBV, we next investigated if
LANA and LMP1 could have an additive effect on uch-l1 expression.
Reporter assays conﬁrmed the previous data demonstrating that
expression of LANA or LMP1 resulted in signiﬁcantly (po0.05)
increased activation of the uch-l1 promoter. Furthermore, when
LANA and LMP1 were co-expressed, there was an additive effect
on activation of the endogenous promoter (Fig. 5A). These ﬁndings
were conﬁrmed by examining UCH-L1 RNA and protein levels
(Fig. 5B and C). Levels of UCH-L1 were signiﬁcantly (po0.05)
greater when LANA and LMP1 were co-expressed than when these
oncoproteins were expressed alone, which were still signiﬁcantly
(po0.05) greater than in cells expressing the vector control.
Further conﬁrmation for the additive effects of LMP1 was
obtained by knocking down LMP1 expression in PEL cells. BC-3
and BC-1 were transfected with either a LMP1-speciﬁc siRNA or a
mutant siRNA, in which two bases were changed (Fig. 5D). Results
showed approximately 40% knockdown in LMP1 RNA levels in BC-
1 cells (dually infected with EBV and KSHV), which corresponded
with a signiﬁcant (po0.05) 35% decrease in relative uch-l1 levels.
No differences in uch-l1 expression were observed in BC-3 cells,
which do not express LMP1. These ﬁndings conﬁrm the additive
effect of LMP1 on uch-l1 expression in dually infected PEL cells.
Activation of the UCH-L1 promoter by RBP-Jκ
Finally, the mechanism by which LANA and LMP1 induce the
uch-l1 promoter was explored. Analysis of the UCH-L1 promoter
sequence with the use of PATCH software (www.gene-regulation.
com) revealed 3 partial putative RBP-J ~κ binding sites. LANA inter-
acts with RBP-Jκ, so the ability of LANA to interact with RBP-Jκ to
activate the uch-l1 promoter was tested. Reporter assays revealed
that LANA and RBP-Jκ separately activated the uch-l1 promoter to
modest, yet signiﬁcant (po0.05), levels. However, co-expression
of LANA and RBP-Jκ resulted in signiﬁcant (po0.05) additive
activation of the endogenous promoter (Fig. 6A). These results
suggest that that KSHV LANA protein activates the uch-l1 promoter
via its interaction with RBP-Jκ.
The ability of RBP-Jκ to activate the uch-l1 promoter during EBV
infection was conﬁrmed by ChIP assays. Using the EBV-transformed
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B cell line KR4, which express high levels of LMP1 as well as high
levels of endogenous UCH-L1 (Bheda et al., 2009a), RBP-Jκ-speciﬁc
antibodies were used to pull down RBP-Jκ DNA complexes. Non-
immunoprecipitated DNA was used as input DNA, and an isotype-
matched IgG antibody served as a negative control. PCR analysis of
portions of the uch-l1 promoter revealed that RBP-Jκ bound to the
UCH-L1 promoter through at least 2 of the 3 partial RBP-Jκ binding
sites (Fig. 6B).
Taken together these data suggest that both KSHV and EBV
encode latency-associated proteins (LANA and LMP1) that inde-
pendently induce the expression of UCH-L1 through the activation
of RBP-Jκ. With dual infection, which is detected in more than 60%
of PELs, KSHV LANA and EBV LMP1 can have an additive effect on
the induction of the expression of UCH-L1, thus potentially
enhancing the tumorigenic phenotype in these cells.
Discussion
Our studies are the ﬁrst to identify a role for KSHV LANA and
EBV LMP1 in the activation of UCH-L1 expression. During cell
transformation by either virus, the induction of the expression of
UCH-L1 is a prominent cellular response (Bheda et al., 2009a,b,
2010,2011; ). Because UCH-L1 expression is linked to multiple,
observed tumorigenic phenotypes in cells, including increases in
cell proliferation, adhesion, migration, and invasion as well as
changes in cell morphology and inhibition of apoptosis, (Bheda
et al., 2009a; Kim et al., 2009; Rolen et al., 2008), the data
presented point to a mechanism by which both viruses can induce
the expression of UCH-L1 and contribute to the oncogenicity of
these viruses (Fig. 7). Furthermore, the two representative PEL cell
lines, one infected only with KSHV and one dually infected with
KSHV and EBV, revealed that the co-infected cells expressed
higher levels of UCH-L1. Indeed, co-expression of KSHV LANA
and EBV LMP1 was associated with signiﬁcantly increased activa-
tion of the uch-l1 promoter as well as UCH-L1 RNA and protein and
pointed to an additive response by these two very different viral
proteins. Knockdown of LMP1 signiﬁcantly lessened the additive
effect of LMP1 in dually infected PEL cells. Together, these data
strongly support the hypothesis that that both of these transform-
ing human γ-herpesviruses activate the uch-l1 promoter, inducing
UCH-L1 expression.
We recently documented that EBV EBNA2 activates the uch-l1
promoter in type III EBV latency (Bheda et al., 2009a,b, 2010, 2011),
resulting in increased UCH-L1 expression (Bheda et al., 2009a,b,
2010, 2011; Soni et al., 2007). However, EBNA2 cannot be respon-
sible for up-regulation of UCH-L1 in co-infected PELs because the
type III latency promoter Cp is not active in EBV-positive PEL cells,
and EBNA2 is not expressed (Carbone et al., 2000; Carbone and
Gloghini, 2005; Fakhari et al., 2006; Sin et al., 2007). Rather, dually
infected PEL cells exhibit a restricted expression pattern of EBV
products and may express low levels of LMP1 (Callahan et al.,
1999). LMP1 expression was detected in co-infected PEL cells,
LMP1 expression alone was capable of inducing the activation of
the uch-l1 promoter and UCH-L1 expression, and knockdown of
LMP1 resulted in decreased uch-l1 expression. These ﬁndings
identify a second EBV latency protein that induces the expression
of UCH-L1 (Fig. 7). However, because LMP1 levels are low in dually
infected PEL cells (Callahan et al., 1999), and knockdown of LMP1
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change7standard deviation for experiments performed in triplicate.
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did not completely abrogate the increase in uch-l1 expression
observed in BC-1 cells compared with BC-3 cells, these ﬁndings
cannot eliminate the possibility that EBNA1 (Bornkamm, 2009;
Kaul et al., 2007) or EBV-encoded non-polyadenylated RNAs
(EBER1 and EBER2) contribute to the up-regulation of uch-l1. Both
EBNA1 and the EBERs have been shown to play roles in malignant
transformation, and because we propose that during transforma-
tion oncogenic viruses activate the uch-l1 promoter; it is possible
and probable that EBNA1 and the EBERs may also induce UCH-L1
expression either directly or indirectly. Therefore, the higher levels
of endogenous UCH-L1 RNA and protein we detected in EBV-
positive PELs (Fig. 3) and EBV-transformed cells (Bheda et al.,
2009a,b, 2010, 2011) may be the cumulative result of more than
one EBV and/or KSHV products.
The role of EBV in PEL co-infection is still unclear. However,
there is evidence for interactions between the two viruses: In vitro
EBV infection of KSHV-infected PEL enhances the tumorigenicity of
the singly infected PEL in SCID mice (Xu et al., 2007); dually-
infected compared with singly KSHV-infected PELs express a
unique set of cellular genes (Fan et al., 2005a); KSHV LANA
activates the expression of EBV latent membrane protein 1
(LMP1) (Groves et al., 2001b), but reduces the expression of EBV
EBNA1 and EBNA2 (Krithivas et al., 2000). Because we show that
co-expression of LANA and LMP1 enhanced activation of the uch-l1
promoter and increased expression of UCH-L1, it is possible that
their additive effects on UCH-L1 expression also occur during
endogenous infection. The effect of UCH-L1 on the tumorigenic
phenotypes of cells has been well documented (Bheda et al.,
2009a; Kim et al., 2009; Rolen et al., 2008). We have speciﬁcally
studied the cellular changes resulting from knockdown of uch-l1 in
EBV-transformed B cells (Bheda et al., 2009a). Our previous results
have documented functions for EBV-induced uch-l1 expression in
cell proliferation, adhesion, and migration as well as inhibition of
apoptosis (Bheda et al., 2009a). Similar results were observed in
different cell lines (independent of viral protein expression)
(Bheda et al., 2009a), suggesting a universal role for uch-l1 in
these phenotypic changes regardless of cell origin and method of
transformation.
The ﬁnding that KSHV LANA can itself induce the expression of
EBV LMP1 (Groves et al., 2001b) suggests there is a second
mechanism through which UCH-L1 levels are augmented in co-
infected cells: LANA activates the expression of LMP1, which in
turn activates the uch-l1 promoter, resulting in greater levels of
UCH-L1. Altogether, because UCH-L1 expression is associated with
the tumorigenic phenotype of transformed cells (Bheda et al.,
2009a; Kim et al., 2009; Rolen et al., 2008), these data suggest that
UCHL1 expression may contribute to enhanced tumorigenesis
in PEL.
During EBV infection, EBNA2 interacts with PU.1 to activate the
uch-l1 promoter (Bheda et al., 2009a,b, 2010, 2011). We now
document that EBV, as well as KSHV, also induces UCH-L1
expression via RBP-Jκ. Our ﬁndings show that RBP-Jκ expression
enhanced LANA-induced activation of the uch-l1 promoter and
that endogenous RBP-Jκ binds to endogenous uch-l1 promoter
sequences in transformed B-cells. While RBP-Jκ itself can activate
the uch-l1 promoter, indicating that RBP-Jκ binds to the promoter
independent of viral protein expression, the strong combined
effect of LANA and RBP-Jκ co-expression on the activity of the
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promoter suggests that LANA interacts with RBP-Jκ and enhances
activation of UCH-L1 expression. However, each factor most likely
activates the endogenous promoter through independent mechanisms
as well. Due to the overlap of the RBP-Jκ sites with other transcription
factor binding sites, including NF-κB binding sites, we did not under-
take mutational analysis of the partial RBP-Jκ binding sites, but these
data do strongly suggest that RBP-Jκ is important in the activation of
the uch-l1 promoter.
In addition to RBP-Jκ, LANA also interacts with SP1, STAT3,
c-JUN (Verma et al., 2007), and the uch-l1 promoter has binding
sites for each of these transcription factors. LMP1 also activates
multiple signaling pathways resulting in the downstream activa-
tion of these factors. Therefore, SP1, STAT3, and c-JUN are likely
candidates to contribute to LANA- and LMP1-induced activation of
the uch-l1 promoter and will be the subject of future studies.
UCH-L1 can also up-regulate its own promoter (Bheda et al.,
2009b). Previously, UCH-L1 was one of many proteins identiﬁed that
co-precipitated with LANA (Paudel et al., 2012), and here we
document that LANA does interact with UCH-L1. Therefore, a third
mechanism by which LANA induces UCH-L1 expression is through its
interaction with UCH-L1, which would result in a positive feed-back
loop, further enhancing UCH-L1 expression following KSHV-
mediated transformation.
Together, these ﬁndings support our hypothesis that in the
process of cellular transformation, tumor viruses activate the uch-l1
promoter, thus inducing UCH-L1 expression. We previously docu-
mented that EBV-induced transformation induced UCH-L1 expres-
sion via EBNA2 and PU.1 (Bheda et al., 2009a,b, 2010, 2011) (Fig. 7),
and now we show KSHV also induces the expression of UCH-L1.
Speciﬁcally, two viral proteins, LANA and LMP1, which are essential
in the viral transformation process, were documented to be sufﬁcient
to activate the uch-l1 promoter via RBP-Jκ, resulting in increased
protein expression. Dual expression of LANA and LMP1, both endo-
genously and exogenously, had an additive effect on UCH-L1 expres-
sion (Fig. 7). Therefore, in the future, it would be interesting to
determine if co-infection with other pairs of viruses, such as HPV and
EBV, also enhances UCH-L1 expression, which in light of their
different mechanisms may combine to enhance viral pathology.
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Finally, we observed that KSHV-infected endothelial cells dis-
play upregulated UCH-L1 and that KSHV LANA induces the
expression of uch-l1 in endothelial cells. Thus, UCH-L1 may also
play a role in the pathogenesis of Kaposi sarcoma.
Materials and methods
Cells
NIH 3T3 and Cos-7 cells were cultured in Dulbecco Modiﬁed
Eagle Medium (DMEM) (Sigma) supplemented with 10% FBS
(Sigma) and penicillin–streptomycin (Sigma). Primary Effusion
Lymphoma cell lines BC-1 (contains both KSHV and EBV genomes)
and BC-3 (contains KSHV), were cultured in RPMI 1640 medium
(Gibco) plus 10% heat-inactivated FBS, 100 units/ml penicillin–
streptomycin, 1% sodium bicarbonate (Sigma) and 0.5% β–ME
(Sigma). All cell lines were maintained at 37 1C in 5% CO2 in air.
Plasmids
pcDNA LANA-Flag construct was a gift from Dr. Dirk Dittmer.
pECE-RBP-Jκ construct was a gift from Dr. Paul Ling. pGL3-UCH-L1
promoter reporter construct was ampliﬁed and cloned as
described (Bheda et al., 2009a). pcDNA LMP1 has been previously
described (Bentz et al., 2011, 2012; Ning et al., 2008).
Luciferase reporter assays
For luciferase assays, cells were seeded in 6-well plates and
transiently transfected with the use of Fugene HD (Roche Diag-
nostics) with UCH-L1p-Luc promoter plasmid, β-gal constructs,
and indicated effector plasmids. The total amount of DNA in all
transfections was kept constant with empty vector. Luciferase
assays were performed 48 h post-transfection as speciﬁed by the
manufacturer (Promega). All reporter-assay results are from three
independent experiments prepared in triplicate and have been
normalized for β-gal activity.
Reverse transcriptase PCR
NIH 3T3 cells were transiently transfected with a total of 2 μg
of DNA with the Fugene HD reagent (Roche Diagnostics). Cells
were collected 48 h post-transfection for RT-PCR analysis. Total
RNA was extracted with the use of Agilent's Total RNA isolation
mini kit per manufacturer's instructions (Agilent Technologies).
500 ng of total RNA were used for RT-PCR reactions using the one
step RT-PCR kit (Qiagen) as per manufacturer's instructions at an
annealing temperature of 55 1C. Samples were analyzed on 1%
agarose gel. Primers used:
UCH-L1: 5′-GGATGGCCACCTCTATGAAC-3′, 5′-AGACCTTGG-
CAGCGTCCT-3′
GAPDH: 5′-AGGTGAAGGTCGGAGTCAACG-3′, 5′-AGGGGTCATT-
GATGGCAACA-3′.
Chromatin immunoprecipitation
ChIP assays were performed using Active Motif ChIP-IT enzy-
matic kit (Active Motif) per manufacturer's instructions. KR4 cells
were ﬁxed with 37% formaldehyde (1% ﬁnal concentration) for
10 min at 37 1C; the reaction was stopped with cold 0.125 M
glycine solution for 5 min at RT. The cells were then washed twice
with PBS and collected in 0.5 ml digestion buffer with 1
protease inhibitors. Chromatin was sheared with shearing enzyme
for 10 min at 37 1C to obtain an average of 200–1000 bp frag-
ments. Sheared chromatin was incubated overnight at 4 1C with
Protein G magnetic beads, and RBP-Jκ antibody (Santa Cruz-H50
X). Immunoprecipitations were performed per the manufacturer's
instructions; cross-linking was reversed by incubating immuno-
precipitated complexes with 5 M NaCl and RNase A (ﬁnal concen-
tration 25 μg /ml) for 2 h at 65 1C followed by Proteinase-K (ﬁnal
concentration 50 μg/ml) treatment for 2 h at 42 1C. PCR reactions
were performed with 5 μl precipitated DNA with primer pairs
ﬂanking consensus RBP-Jκ sites in UCH-L1 promoter. PCR condi-
tions: one cycle, 95 1C for 2 min; 30 cycles at 95 1C for 30 s, 55 1C
for 30 sec, and 72 1C for 2 min, and a ﬁnal extension at 72 1C for
10 min. The primers used in the reaction were:
Site 1 (5′ CCTGTTGAATTTGTGCT 3′;
5′ CGCCGGTGAGATAATCTG 3′)
Site 2/3 (5′ GCTCCATACACTCAAGGAAC 3′;
5′ GCCAGACGCACTGTGA 3′)
Western blotting
Total cell lysates were resolved on 12% SDS-PAGE, transferred to
PVDF membrane (GE Healthcare), blocked in 5% milk-Tris-buffered
saline solution, and incubated at 4 1C overnight with UCH-L1
(1:7500, Invitrogen) and GAPDH (1:5000, Sigma) antibodies fol-
lowed with horse-radish peroxidase-conjugated secondary anti-
bodies. Proteins were detected with Super Signal West Pico
Chemiluminescence Detection Kit (Pierce Biotechnology, Rockford,
IL, USA) and exposed to Kodak XAR-5 ﬁlm.
Immunoprecipitation
KR4 cells were lysed with buffer containing 50 mM Tris–HCl,
pH 7.6, 1% NP-40, 0.25% Na-deoxycholate, 1 mM EDTA, 1 mM
Na3Ov4, 1 mM NaF and complete protease inhibitor mixture
(Roche Diagnostics). Cell lysates were incubated with anti-Flag
beads (Sigma) incubated at 4 1C overnight, washed four times with
protein lysis buffer, and then eluted from protein anti-Flag beads
with 2 Laemmli's buffer.
2D-Gel electrophoresis
Cells were harvested and washed three times with PBS. The cell
pellets were lysed with lysis buffer (10 mM Tris, pH 7.4, and 0.3%
SDS) and incubated for 30 min on ice. Equivalent micrograms of
protein were subjected to 2D gel electrophoresis by the UNC
Proteomics Center. The 2D gels were stained with Coomasie blue.
Unique spots were identiﬁed and sequenced by MALDI TOF/TOF
mass spectrometry.
LMP1 Knockdown
BC-1 and BC-3 cells were transiently transfected with siRNA
speciﬁc for LMP1 (siRNA LMP1 5′-GGAAUUUGCACGGACAGGCUU-
3′) or with a two-base mutation (siRNA mut 5′-GGAAUGUGCACA-
GACAGGCUU-3′) using Amaxas Cell Line Nucleofectors Kit V.
Nucleofections were performed at 0 and 24 h, and cells were
harvested at 72 h. RNAwas isolated and RT-PCR was performed for
GAPDH, UCH-L1, and LMP1 (as described above). pmaxGFPs
Vector was used as a transfection control; the transfection efﬁ-
ciencies were approximately 30%.
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